5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
Image Source: Pixabay
The 5 constituents in the munKNEE Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. Below is how each constituent stock performed last week, in descending order, and MTD, and any recent news, commentary, and/or analysis on each company:
- Compass Pathways (CMPS): UP 33.1% last week; UP 22.2% MTD
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest News, Commentary and/or Analysis:
- None
- GH Research (GHRS): UP 23.9% last week; UP 25.0% MTD
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Latest News, Commentary and/or Analysis:
- Mind Medicine (MNMD): UP 2.8% last week; UP 0.8% MTD
- Atai Life Sciences (ATAI): UP 1.2% last week; UP 22.0% MTD
- Incannex Healthcare (IXHL): DOWN 7.4% last week; DOWN 19.4% MTD
- is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Latest News, Commentary and/or Analysis:
Summary
The munKNEE Psychedelic Drug Stocks Index went UP 16.7% last week and is now up 11.7% MTD.
More By This Author:
Quantum Computing Hardware Developers Index Up Last Week
Conservative "Cannabis" Stocks Down Last Week; What You Need To Know
These 7 Cannabis MSO Stocks Advanced 5% Last Week
Disclosure: None
Visit munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample more